Stoke Therapeutics Q3 revenue beats estimates on Acadia, Biogen agreements

Stoke Therapeutics

04/11/2025 21:22

Overview

Stoke Therapeutics Q3 revenue grows to $10.6 mln, beating analyst expectations

Net loss for Q3 2025 was $38.3 mln, compared to $26.4 mln in Q3 2024

Company progressing with Phase 3 EMPEROR study for zorevunersen

Outlook

Stoke plans to complete Phase 3 EMPEROR study enrollment by H2 2026

Company to meet FDA by year-end 2025 for expedited zorevunersen approval

Stoke to activate European sites for STK-002 study in early 2026

Result Drivers

CONTRACTUAL AGREEMENTS - Revenue increase driven by obligations under agreements with Acadia and Biogen

FINANCIAL POSITION - Strong cash reserves allowing investment in business and pipeline expansion

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$10.63 mln
$6.16 mln (10 Analysts)
Q3 Net Income
-$38.34 mln
Q3 Operating Expenses
$53.72 mln
Q3 Operating Income
-$43.09 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Stoke Therapeutics Inc is $30.00, about 13% above its November 3 closing price of $26.10

Press Release: ID:nBw6Qvycwa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)